NCT02143440Unknown不适用
The Initial Assessment of Daily Insulin Dose in Newly Diagnosed Type 2 Diabetes
适应症
干预措施
试验速览
- 阶段
- 不适用
- 入组人数
- 65
- 试验地点
- 1
- 主要终点
- When the glucose level decreased to about 10 mmol/L
研究概览
简要总结
To investigate the daily dose of insulin in newly diagnosed Chinese type 2 diabetic patients who use the continuous subcutaneous insulin infusion (CSII) as the initial therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All participants with type 2 diabetes, diagnosed by World Health Organization criteria, were recruited from outpatient of the Endocrinology Department in Shanghai Renji Hospital.
排除标准
- •Patients who had a history of coronary heart disease, abnormal renal function, active liver disease, chronic metabolic acidosis (including diabetic ketoacidosis), or severe chronic gastrointestinal disease.
研究组 & 干预措施
Newly diagnosed type 2 patients
Other
The initial assessment of daily insulin dose.
干预措施: The initial assessment of daily insulin dose. (Behavioral)
结局指标
主要结局
When the glucose level decreased to about 10 mmol/L
时间窗: 72-96 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Insulin Dose Titration System Using a Short Messaging Service (SMS) Automatically Produced by a Knowledge MatrixDiabetes Mellitus, Type 2NCT00948584Hallym University Medical Center100
已完成
不适用
Study on insulin treatment for type 2 diabetes performed by general practitionersType 2 diabetes mellitusJPRN-UMIN000011287General incorporated Tokyo Physicians Association.100
Unknown
不适用
A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily InjectionsDiabetes Mellitus Type 1NCT01045954Diabetes Care Center50
已完成
3 期
A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take InsulinDiabetes Mellitus, Type 2NCT04233801Boehringer Ingelheim219
撤回
1 期
A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection TherapyDiabetes Mellitus, Type 2NCT02623465Eli Lilly and Company